文献速递基础与转化研究临床试验与 GCP

CD4+ T细胞介导BCMA CAR-T细胞治疗后的免疫相关不良事件

CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy.
PubMed 文献 · Nat Med · 2026-01-15

在2021年6月至2024年12月接受西达基奥仑赛或艾基奥仑赛治疗的198例多发性骨髓瘤患者中,27例(13.6%)发生CAR-T细胞治疗相关免疫相关不良事件(CirAEs)。CirAEs与显著更高的非复发死亡率相关(HR=5.2,P=0.006),独立危险因素包括西达基奥仑赛(OR=4.5,P=0.058)、输注后14天内峰值绝对淋巴细胞计数≥2.4×10^3/μL(OR=4.3,P<0.001)及单采CD4:CD8比值>1(OR=2.6,P=0.048)。所有可获得的CirAE组织中均发现显著CD4+ CAR-T细胞浸润,提示CD4+ CAR-T细胞是这些毒性的关键介导者。

要点

  • 198例接受BCMA CAR-T治疗的患者中27例(13.6%)发生CirAEs。
  • CirAEs与显著更高的非复发死亡率相关(HR=5.2,P=0.006)。
  • 所有可获得的CirAE组织中均见显著CD4+ CAR-T细胞浸润。

核心结论

  • CD4+ CAR-T细胞是BCMA CAR-T细胞治疗相关免疫相关不良事件(CirAEs)的关键介导者。

研究设计与样本

  • 研究纳入2021年6月至2024年12月接受西达基奥仑赛或艾基奥仑赛治疗的198例患者,其中27例(13.6%)发生CirAEs。

主要发现

  • 198例患者中27例(13.6%)发生CirAEs。
  • CirAEs与显著更高的非复发死亡率相关(HR=5.2,P=0.006)。
  • 独立危险因素包括西达基奥仑赛(OR=4.5,P=0.058)、输注后14天内峰值绝对淋巴细胞计数≥2.4×10^3/μL(OR=4.3,P<0.001)及单采CD4:CD8比值>1(OR=2.6,P=0.048)。
  • 一例患者出现三种不同CirAEs并伴极端CD4+ CAR-T细胞扩增(峰值淋巴细胞197×10^3/μL),体外可被CCR5抑制所消除。
  • 所有可获得的CirAE组织中均发现显著CD4+ CAR-T细胞浸润,包括神经系统CirAEs期间的脑脊液。

关键数值与推荐

  • CirAEs与更高的非复发死亡率相关(HR=5.2,P=0.006)。
  • 西达基奥仑赛的OR=4.5(P=0.058)。
  • 输注后14天内峰值绝对淋巴细胞计数≥2.4×10^3/μL的OR=4.3(P<0.001)。
  • 单采CD4:CD8比值>1的OR=2.6(P=0.048)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of multiple myeloma but can cause unique toxicities, including cranial nerve palsy, parkinsonism and enterocolitis, which we refer to collectively as CAR T cell therapy-associated immune-related adverse events (CirAEs). Among 198 patients treated with ciltacabtagene autoleucel or idecabtagene vicleucel (June 2021-December 2024), 27 (13.6%) developed CirAEs. This included one remarkable case with three distinct CirAEs in association with an extreme CD4+ CAR T cell expansion (peak lymphocytes: 197 × 103 per microliter), which was abrogated in vitro by CCR5 inhibition. CirAEs were associated with significantly higher non-relapse mortality (hazard ratio = 5.2, P = 0.006), and independent risk factors included ciltacabtagene autoleucel (odds ratio = 4.5, P = 0.058), peak absolute lymphocyte count ≥ 2.4 × 103 per microliter in the first 14 days post-infusion (odds ratio = 4.3, P < 0.001) and apheresis CD4:CD8 ratio > 1 (odds ratio = 2.6, P = 0.048). We identified marked CD4+ CAR T cell infiltration in all available CirAE tissues, including cerebrospinal fluid during neurologic CirAEs, implicating CD4+ CAR T cell therapy as a key mediator of these toxicities.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Ho M, Paruzzo L, Noll JH, et al. CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy. Nat Med. 2026. PMID: 41540109. doi:10.1038/s41591-025-04121-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。